REHOVOT, ISRAEL – May 28, 2024 NeoTX Therapeutics (NeoTX), a clinical-stage immuno-oncology drug development company, announced abstract acceptance at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting being held May 31- June 4, 2024, at the McCormick Place, Chicago, IL. The poster will present preliminary results of clinical activity and safety of naptumomab estafenatox (NAP) and docetaxel in a phase 2 trial in patients with advanced/ metastatic non-small cell lung cancer (NSCLC) which have been pretreated with standard chemotherapy and a checkpoint inhibitor (CPI). Details on the presentation are as follows:

• Abstract Title:
  Clinical Activity and Safety of Naptumomab Estafenatox (NAP) and Docetaxel in Patients (pts) with Checkpoint Inhibitor (CPI) Pre-treated Advanced/ Metastatic Non-Small Cell Lung Cancer (NSCLC) – Preliminary Results, P2 Trial
• Abstract Number:
  8615
• Session Type and Title:
  Poster Session – Lung Cancer—Non-Small Cell Metastatic
• Session Date & Time:
  Monday June 3, 2024, 1:30 PM – 4:30 PM CDT

  About NeoTX NeoTX is a clinical-stage immuno-oncology company which is developing targeted anticancer immunotherapies utilizing its proprietary Tumor Targeted Superantigen (TTS) platform. TTS binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor specific immune cells that are then redirected from the periphery to the tumor to mount an immune response. The company’s lead TTS molecule, naptumomab estafenatox (NAP) is currently in clinical development for advanced solid tumors. For more information, please visit www.neotx.com Investor and Media Contact: Robert Harow, CFOO NeoTX Therapeutics Ltd robert@neotx.com +1 609-718-2305 x204 +972 3 912 5853 x204